Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine aims to control or cure chronic hepatitis b

NCT ID NCT03038802

Not yet recruiting Disease control Sponsor: Vaxine Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tests a new therapeutic vaccine (Hepadvax) in 40 adults with chronic hepatitis B. The vaccine is designed to boost the immune system to control or possibly clear the virus. Researchers will monitor safety, viral load, and immune responses compared to a standard hepatitis B vaccine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Therapeutic hepatitis B vaccine (Hepadvax) with Advax-2 adjuvant
What this could lead to
If successful, this vaccine could help control or even clear chronic hepatitis B infection, reducing the need for lifelong antiviral medication.
What could go wrong
This is an early phase 1/2 trial with only 40 participants, so results may not apply broadly. The vaccine may not effectively reduce viral load or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • ARASMI

    Adelaide, South Australia, 5046, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.